

Pharmacy Formulary Updates for August 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in August 2021:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
abiraterone 500 mg	Tier 2; PA; SP
Amondys 45 (casimersen)	MB; PA
Jemperli (dostarlimab-gxly)	MB
Nulibry (fosdenopterin)	MB; PA
Ponvory (ponesimod)	NC, SP, QL (starter pack: 1 fill per lifetime, 20 mg tablets: 30/30)
Zynlonta (loncastuximab tesirine-lpyl)	MB
Zegalogue® (dasiglucagon) subcutaneous injection	NC
Exservan (riluzole)	Tier 3
sumatriptan	Tier 2; QL; 3 kits/30 days (6 injections or vials)/30 days
Imitrex	NC; QL; 3 kits/30 days (6 injections or vials)/30 days
Fulphila	Tier 2; PA; QL; 0.6 mL/14 days
Moviprep	NC
pregabalin tab ER 24Hr	NC
isotretinoin cap	NC
bepotastine besilate ophth soln 1.5%	Tier 2
rufinamide	Tier 2; QL
arformoterol tartrate soln nebu 15 mcg/2ml	Tier 2
lopinavir-ritonavir	Tier 2
Focalin (2.5mg)	NC
Clenpiq	\$0 cost share to members age 45-75 years old
Plenvu	
Suprep	
Sutab	
Peg 3350/electrolytes	

Peg-Prep	\$0 cost share to members age 45-75 years old
Gavilyte C	
Gavilyte G	
PEG-3350/electrolytes	
Golytely packet	
PEG-3350/electrolytes	
Gavilyte-N	

Key:

- | | |
|--------------------------------|--|
| MB: Medical Benefit | QL: Quantity Limitation |
| NC: Not Covered | SP: Specialty Pharmacy - provided through CVS/specialty |
| NTM: New-to-Market | ST: Step Therapy |
| PA: Prior Authorization | |